Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Alzheimer's Association announces new research grants to study potential drug therapies

Alzheimer's Association announces new research grants to study potential drug therapies

Many academic researchers and pharmaceutical companies have identified new Alzheimer's drug therapy candidates, but lack the funding to move them into human testing. At the same time, few funding sources support early-phase clinical drug trials. As a result, too many promising studies stall out early in the discovery process. [More]
Study: Targeted biopsy technique better than standard biopsy at detecting high-risk prostate cancer

Study: Targeted biopsy technique better than standard biopsy at detecting high-risk prostate cancer

Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance/ultrasound fusion biopsy, compared with a standard biopsy technique, was associated with increased detection of high-risk prostate cancer and decreased detection of low-risk prostate cancer, according to a study in the January 27 issue of JAMA. [More]
Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Purdue University researchers find promising way to treat late-stage prostate cancer

Purdue University researchers find promising way to treat late-stage prostate cancer

Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds. [More]
Cleveland Clinic researcher awarded grant to advance treatment of lethal prostate cancer

Cleveland Clinic researcher awarded grant to advance treatment of lethal prostate cancer

The Prostate Cancer Foundation has presented Nima Sharifi, M.D., Kendrick Family Endowed Chair for Prostate Cancer Research at Cleveland Clinic's Lerner Research Institute, a Challenge Award to advance the treatment of lethal prostate cancer. He is also co-investigator on a second Challenge Award that was also selected for funding. [More]
Study identifies gene that may become resistant to current testicular cancer treatments

Study identifies gene that may become resistant to current testicular cancer treatments

A major research study has uncovered several new genetic mutations that could drive testicular cancer - and also identified a gene which may contribute to tumours becoming resistant to current treatments. [More]
Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison. [More]
VolitionRx initiates pilot study to assess effectiveness of NuQ assays for ovarian cancer

VolitionRx initiates pilot study to assess effectiveness of NuQ assays for ovarian cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced it has signed an agreement to commence a pilot ovarian cancer study in collaboration with Singapore General Hospital. [More]
MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

Gold nanoparticles have been proven useful in a number of medical applications. Scientists are developing nanoparticles to produce pharmaceuticals used in the imaging and diagnosis of diseases such as cancer, arthritis, Parkinson's disease and eye degeneration. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Research opens door to potential new cancer biomarkers

Research opens door to potential new cancer biomarkers

A new analysis opens the door to discovery of thousands of potential new cancer biomarkers. [More]
GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]
ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix, Inc., a leading provider of cloud-based healthcare analytics solutions, today announced that the Urology Department of the University of North Carolina School of Medicine is using its cloud-based RegistryMetrix analytics platform. [More]
Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

GenomeDx Biosciences today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the company's Decipher prostate cancer classifier. [More]
Lung cancer rates are lower in higher-elevation counties, new study finds

Lung cancer rates are lower in higher-elevation counties, new study finds

Here's another potential reason to live up in the mountains. Lung cancer rates in both smokers and non-smokers are lower in higher-elevation counties in the western part of the United States, suggesting that oxygen may promote the incidence of lung cancer, according to a new study co-authored by a student at the Perelman School of Medicine at the University of Pennsylvania. [More]
Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

The ancient physician/alchemist, Paracelsus, said: "The dose makes the poison." According to a new study published in PeerJ, even oxygen may fall prey to the above adage. While essential to human life, aspects of oxygen metabolism may promote cancer. Capitalizing on the inverse relationship of oxygen concentration with elevation, researchers found lower rates of lung cancer at higher elevations, a trend that did not extend to non-respiratory cancers, suggesting that carcinogen exposure occurs via inhalation. [More]
Family history could help physicians identify prostate cancer risk

Family history could help physicians identify prostate cancer risk

A discovery by researchers at Huntsman Cancer Institute shows that looking at whether a man's uncles and great-grandparents, among other second- and third-degree relatives, had prostate cancer could be as important as looking at whether his father had prostate cancer. A more complete family history would give physicians a new tool to decide whether or not a PSA test was appropriate. [More]

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity. [More]
Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer. [More]
New imaging technique measurably improves prostate cancer screening

New imaging technique measurably improves prostate cancer screening

In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men. Writing in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging - and may have significant implications for how patients with prostate cancer are ultimately treated. [More]